MANTLE-CELL LYMPHOMA

This study tested a new drug called BGB-10188, alone or combined with other cancer drugs, in 97 people with certain blood cancers (like lymphoma and leukemia) or advanced solid tumors. The main goals were to find safe doses and check for side effects. The trial was completed, but…

This study looked at a new way to do bone marrow transplants for people with blood cancers like leukemia and lymphoma who don't have a perfectly matched donor. Instead of using a standard drug after transplant, doctors tested a different drug called bendamustine to see if it coul…

This study tested an oral drug called LOXO-305 (pirtobrutinib) in 803 people with chronic lymphocytic leukemia, small lymphocytic lymphoma, or other non-Hodgkin lymphomas whose cancer had stopped responding to or could not tolerate standard treatments. The goal was to find the be…

This study tested a two-part chemotherapy plan (EDOCH and DHAP) with or without the targeted drug rituximab for people 65 and younger newly diagnosed with mantle cell lymphoma. The goal was to see how well the treatment controlled the disease and whether adding rituximab helped. …

This study tested a less intense stem cell transplant for people with various blood cancers who are older or have other health issues. It used a half-matched family donor (like a parent or sibling) and a milder chemo and radiation preparation. The goal was to see how many patient…

This study looked at 174 adults with blood cancers who received a stem cell transplant from an unrelated donor. Researchers compared different combinations of immune-suppressing drugs to find the best way to prevent graft-versus-host disease (GVHD), a serious complication where d…

This study tested a drug called zanubrutinib in 96 people with certain types of B-cell lymphoma who had severe side effects from similar drugs (ibrutinib or acalabrutinib). The goal was to see if zanubrutinib caused fewer or milder side effects while still controlling the cancer.…

This study tested a new radiation schedule (once a week for 5 weeks) in 10 people with B-cell lymphoma that had come back or not responded to treatment. The goal was to see if this approach is practical and has fewer side effects before patients receive CAR T-cell therapy. The st…

This study tested a drug called obinutuzumab added to standard chemotherapy and a stem cell transplant for people with mantle cell lymphoma, a rare blood cancer. 86 patients received the treatment and then maintenance therapy. The goal was to see if this approach could better con…

This study tested whether giving the drug bortezomib after intensive chemotherapy, immunotherapy, and a stem cell transplant could help keep mantle cell lymphoma from coming back. 151 patients took part. The goal was to see if this approach improved how long people lived without …

This early-phase study tested an experimental therapy called PRGN-3007 UltraCAR-T cells in 3 adults with advanced blood cancers (like leukemia and lymphoma) or triple-negative breast cancer. The main goal was to find the safest dose and see if the treatment could shrink tumors. B…

This study tested a combination of the targeted drug acalabrutinib with chemotherapy in 13 people newly diagnosed with mantle cell lymphoma, a rare blood cancer. The goal was to see if the treatment is safe and helps collect stem cells for a future transplant. Results suggest the…

This study reviewed PET scans from 200 adults with mantle cell lymphoma to see if they could improve staging and outcome predictions compared to standard CT scans and bone marrow biopsies. Researchers analyzed scans taken at diagnosis, after initial treatment, and after stem cell…

This study created a registry of 227 adults with mantle cell lymphoma who had started a new type of drug therapy within the past 6 months. Researchers collected information on which treatments were used, how long patients stayed on them, and how patients felt about their quality …